Peripheral T Cell Lymphoma Clinical Trials

16 studies are recruiting for peripheral t cell lymphoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

   Background: Chemokine receptor 4 (CCR4) is a protein that is found on the surface of certain T-cell lymphoma cells and is common in mature T-cell cancers. White blood cells can be changed with molecules called anti-CCR4 to express a chimeric antigen receptors (CAR), which is a molecule that directs…

   Stage

   Phase 1

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT07055477 on ClinicalTrials.gov

2. Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

   Patients are in 2 cohorts: Cohort 1: dexamethasone, methotrexate, ifosfamide, pegaspargase, and etoposide (modified SMILE) chemotherapy regimen alone and pembrolizumab in children, adolescents, and young adults with advanced stage NK lymphoma and leukemia Cohort 2: combining pralatrexate (PRX) (Cyc…

   Stage

   EARLY_Phase 1

   Ages

   1 to 31

   Site

   University of Alabama, Birmingham, Alabama

   Locations

   6 in total

   Run by

   New York Medical College

   See if you can join NCT03719105 on ClinicalTrials.gov

3. Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)

   The SCORE-NHL study is a prospective, multi-center, study designed to collect data and biological samples from participants diagnosed with aggressive Stage I to IV non-Hodgkin Lymphoma (NHL). Study participants will undergo research blood collections of up to 60 mL as well as residual tissue collec…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Natera, Inc., Austin, Texas

   Run by

   Natera, Inc.

   See if you can join NCT07750886 on ClinicalTrials.gov

4. A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma

   This research is being done to study the safety of implanting and retrieving a microdevice that releases up to 19 drugs directly within a cancerous lesion as a possible tool to evaluate the effectiveness of several approved cancer drugs against cutaneous T cell lymphoma and peripheral T cell lympho…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT04045470 on ClinicalTrials.gov

5. To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

   Part 1: This is a 5 Arm study primarily to determine the best dose out of the two dose levels of Belinostat and Pralatrexate combined with CHOP/COP in newly diagnosed PTCL patients based on Safety for part 2 study. Part 2 (Efficacy and Safety): This is a 3 Arm study. Patients with previously untrea…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of California, San Francisco Fresno, Clovis, California

   Locations

   69 in total

   Run by

   Acrotech Biopharma Inc.

   See if you can join NCT06072131 on ClinicalTrials.gov

6. Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

   This study involves patients with diffuse large B cell lymphoma (DLBCL), natural killer/T-cell lymphoma (NKTL), or classical Hodgkin lymphoma (cHL) (referred to collectively as lymphoma) whose disease has returned or not responded to treatment. Previous research combined antibodies and T cells to t…

   Stage

   Phase 1

   Ages

   12 to 75

   Site

   Houston Methodist Hospital, Houston, Texas

   Locations

   2 in total

   Run by

   Baylor College of Medicine

   See if you can join NCT06176690 on ClinicalTrials.gov

7. Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

   This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus (VSV) carrying the human (h) sodium iodide symporter (NIS) and Interferon (IFN) beta (β) genes (VSV-hIFNβ-NIS) in combination with cemiplimab in patients with T-cell lymphoma. A virus, called VSV-hIF…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic in Arizona, Scottsdale, Arizona

   Locations

   2 in total

   Run by

   Mayo Clinic

   See if you can join NCT06508463 on ClinicalTrials.gov

8. Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

   A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Emory Winship Cancer Institute, Atlanta, Georgia

   Locations

   39 in total

   Run by

   CellCentric Ltd.

   See if you can join NCT04068597 on ClinicalTrials.gov

9. Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

   The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, n…

   Stage

   Not phased

   Ages

   0 to 38

   Site

   Children's Hospital Colorado, Aurora, Colorado

   Locations

   5 in total

   Run by

   Children's Hospital Medical Center, Cincinnati

   See if you can join NCT06131801 on ClinicalTrials.gov

10. Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

    This phase II trial tests how well ruxolitinib as a maintenance medication works to prevent relapse and graft-versus-host disease (GVHD) for patients who have undergone stem cell transplantation for T-cell lymphoma. GVHD is a common problem that may occur after a blood stem cell transplant. The "gr…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Ohio State University Comprehensive Cancer Center, Columbus, Ohio

    Run by

    Jonathan Brammer

    See if you can join NCT07356245 on ClinicalTrials.gov

11. A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

    To learn if the study drug golidocitinib given alone or in combination with the standard drug combination therapy called CHOP can help to control PTCL.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06630091 on ClinicalTrials.gov

12. Evaluate the Safety and Clinical Activity of HH2853

    This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and phase II. HH2853 will be administered orally on a continuous BID schedule on a continuous 28-day treatment cycle.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui

    Locations

    25 in total

    Run by

    Haihe Biopharma Co., Ltd.

    See if you can join NCT04390737 on ClinicalTrials.gov

13. Amping up With PemJAK

    The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractory Hodgkin and non-Hodgkin lymphomas.

    Stage

    Phase 2

    Ages

    18 to 95

    Site

    Columbia University Irving Medical Center, New York, New York

    Run by

    Seda S. Tolu

    See if you can join NCT07283822 on ClinicalTrials.gov

14. CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

    This is a research study to determine the safety and tolerability of ATLCAR.CD30 for treating relapsed/refractory Peripheral T Cell Lymphoma. Blood samples will be collected from study participants and the immune T cells will be separated. T cells will be genetically modified in a laboratory at UNC…

    Stage

    Phase 2

    Ages

    18 to 99

    Site

    Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina

    Locations

    2 in total

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT04083495 on ClinicalTrials.gov

15. Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

    This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic Arizona, Scottsdale, Arizona

    Locations

    10 in total

    Run by

    SciTech Development, Inc.

    See if you can join NCT04234048 on ClinicalTrials.gov

16. Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.

    This study T-Cell Project 2.0 is based on the former International PTCL study designed by the International T-cell Non-Hodgkin's Lymphoma Study Group (T-Cell Project 1.0: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma) as a prospective collection of data to predict the p…

    Stage

    Not phased

    Ages

    18 and older

    Site

    IRCCS Istituto Tumori "Giovanni Paolo II", Bari,

    Locations

    6 in total

    Run by

    Associazione Angela Serra per la ricerca sul cancro

    See if you can join NCT03964480 on ClinicalTrials.gov